RU96122812A - METHOD FOR CORRECTION OF FUNCTIONAL STATE OF THE ORGANISM - Google Patents

METHOD FOR CORRECTION OF FUNCTIONAL STATE OF THE ORGANISM

Info

Publication number
RU96122812A
RU96122812A RU96122812/14A RU96122812A RU96122812A RU 96122812 A RU96122812 A RU 96122812A RU 96122812/14 A RU96122812/14 A RU 96122812/14A RU 96122812 A RU96122812 A RU 96122812A RU 96122812 A RU96122812 A RU 96122812A
Authority
RU
Russia
Prior art keywords
solution
administration
functional state
blood
patient
Prior art date
Application number
RU96122812/14A
Other languages
Russian (ru)
Other versions
RU2132192C1 (en
Inventor
О.Е. Колесова
Л.М. Алексеева
Т.Ю. Уханова
В.Я. Зайцев
Original Assignee
Российская медицинская академия последипломного образования Министерства здравоохранения РФ
Filing date
Publication date
Application filed by Российская медицинская академия последипломного образования Министерства здравоохранения РФ filed Critical Российская медицинская академия последипломного образования Министерства здравоохранения РФ
Priority to RU96122812/14A priority Critical patent/RU2132192C1/en
Priority claimed from RU96122812/14A external-priority patent/RU2132192C1/en
Publication of RU96122812A publication Critical patent/RU96122812A/en
Application granted granted Critical
Publication of RU2132192C1 publication Critical patent/RU2132192C1/en

Links

Claims (2)

1. Способ коррекции функционального состояния организма, включающего внутривенное введение в организм озонированного раствора, отличающийся тем, что в качестве озонированного раствора используют раствор 0,9% хлористого натрия, содержащего озон в концентрации 2 - 6 мг/л, который вводят однократно в объеме 200 - 400 мл, причем до и после введения - на 3, 7, 14 день в крови пациента определяют концентрацию глутатиона или небелковых SН групп плазмы и при отсутствии снижения этих показателей относительно исходного уровня, производят повторное введение, но не раньше, чем через 4 дня.1. A method of correcting the functional state of the body, including intravenous administration of an ozonized solution into the body, characterized in that a solution of 0.9% sodium chloride containing ozone in a concentration of 2-6 mg / l, which is administered once in a volume of 200, is used as an ozonized solution. - 400 ml, and before and after administration - on the 3rd, 7th, 14th day in the patient’s blood, the concentration of glutathione or non-protein SN groups of the plasma is determined and, in the absence of a decrease in these indicators relative to the initial level, re-administration is carried out, for no sooner than 4 days later. 2. Способ по п.1, отличающийся тем, что при бактериальных инфекциях в крови пациента дополнительно определяют соотношение диеновых коньюгатов к средним молекулярным пептидам и при значении этого показателя выше 2 Ед, проводят повторное введение раствора. 2. The method according to claim 1, characterized in that in case of bacterial infections in the patient’s blood, the ratio of diene conjugates to the average molecular peptides is additionally determined, and when the value of this indicator is above 2 Units, the solution is repeated.
RU96122812/14A 1996-11-29 1996-11-29 Method of human organism adaptation in pathological processes accompanying with metabolic disorders RU2132192C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU96122812/14A RU2132192C1 (en) 1996-11-29 1996-11-29 Method of human organism adaptation in pathological processes accompanying with metabolic disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU96122812/14A RU2132192C1 (en) 1996-11-29 1996-11-29 Method of human organism adaptation in pathological processes accompanying with metabolic disorders

Publications (2)

Publication Number Publication Date
RU96122812A true RU96122812A (en) 1999-03-20
RU2132192C1 RU2132192C1 (en) 1999-06-27

Family

ID=20187722

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96122812/14A RU2132192C1 (en) 1996-11-29 1996-11-29 Method of human organism adaptation in pathological processes accompanying with metabolic disorders

Country Status (1)

Country Link
RU (1) RU2132192C1 (en)

Similar Documents

Publication Publication Date Title
HOFFMAN et al. Pharmacodynamics of carbenicillin in hepatic and renal failure
WOODWARD et al. Management of typhoid fever and its complications
GOODWIN et al. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels
EP0163723B1 (en) Ddavp antidiuretic and method therefor
US6720011B1 (en) Injectable composition for cancer treatment
EP0502313B1 (en) Method for insuring adequate intracellular glutathione in tissue
EP0973563A1 (en) System, method and composition for dialysis and shock treatment
EP2338495A1 (en) Iron bis-glycinate chelate for use in the oral treatment of anemia in patients with celiac disease
RU96122812A (en) METHOD FOR CORRECTION OF FUNCTIONAL STATE OF THE ORGANISM
Veysi et al. Superior mesenteric artery syndrome presenting with acute massive gastric dilatation
US5620604A (en) Dialysis system and method for removing toxic matter from the serum of the large intestine
Swick et al. Peritoneal dialysis in colistin intoxication: Report of a case
JPH03135918A (en) Immune-activating agent
US6126832A (en) Composition for dialysis and shock treatment
Kosmidis et al. Cefuroxime in renal insufficiency: therapeutic results in various infections and pharmacokinetics including the effects of dialysis
JPH01132527A (en) Intestine washing solution
CN105213301B (en) Netilmicin sulfate injection and its quality control method
Wise Clinical pharmacokinetics of spiramycin
Pérez-Fontán et al. AspergillusPeritonitis Complicating Continuous Ambulatory Peritoneal Dialysis
Woods Susceptibility to experimental pyelonephritis when hormonal hypertension is prevented by hypotensive drugs
Bergogne-Berezin et al. Cefuroxime: pharmacokinetic study in bronchial secretions
GB2207050A (en) Parenteral drug delivery composition
Brogard et al. Experimental and clinical pharmacology of metampicillin in the biliary tract
US5108743A (en) Method of treating primary cancers of the pleura
RU2166944C2 (en) Plasma substitute solution with hemocorrecting and immunomodulating properties